Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC). Grivas, P., Vogelzang, N. J., Alva, A., Feyerabend, S., Loriot, Y., Necchi, A., Gupta, S., Josephs, D., Rodriguez-Vida, A., Srinivas, S., Zakharia, Y., Wride, K., Thomas, D., Dusek, R., Simmons, A., Nepert, D. L., Chowdhury, S. AMER SOC CLINICAL ONCOLOGY. 2019
View details for DOI 10.1200/JCO.2019.37.7_suppl.TPS496
View details for Web of Science ID 000489108800029